Automatic identification of risk factors for SARS-CoV-2 1 positivity and severe clinical outcomes of COVID-19 using Data 2 Mining and Natural Language Processing 3 4 5 Authors: Verena Schöning<sup>1</sup>, Evangelia Liakoni<sup>1</sup>, Jürgen Drewe<sup>2</sup>, Felix Hammann<sup>1,\*</sup> 6 7 8 (1) Clinical Pharmacology and Toxicology, Department of General Internal 9 Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, 10 Switzerland 11 (2) Department of Clinical Pharmacology, University Hospital Basel, Basel, 12 Switzerland 13 14 \* Corresponding Author: 15 Felix Hammann, MD, PhD 16 Clinical Pharmacology and Toxicology, Department of General Internal 17 Medicine, Inselspital, Bern University Hospital, Freiburgstrasse, 3010 Bern, 18 Switzerland 19 Felix.Hammann@insel.ch 20 21 Keywords 22 SARS-CoV-2, COVID-19, risk factors, electronic health records, natural 23 language processing

24

# **ABSTRACT**

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Objectives: Several risk factors have been identified for severe clinical outcomes of COVID-19 caused by SARS-CoV-2. Some can be found in structured data of patients' Electronic Health Records. Others are included as unstructured free-text, and thus cannot be easily detected automatically. We propose an automated real-time detection of risk factors using a combination of data mining and Natural Language Processing (NLP). Material and methods: Patients were categorized as negative or positive for SARS-CoV-2, and according to disease severity (severe or non-severe COVID-19). Comorbidities were identified in the unstructured free-text using NLP. Further risk factors were taken from the structured data. Results: 6250 patients were analysed (5664 negative and 586 positive; 461 non-severe and 125 severe). Using NLP, comorbidities, i.e. cardiovascular and pulmonary conditions, diabetes, dementia and cancer, were automatically detected (error rate ≤2%). Old age, male sex, higher BMI, arterial hypertension, chronic heart failure, coronary heart disease, COPD, diabetes, insulin only treatment of diabetic patients, reduced kidney and liver function were risk factors for severe COVID-19. Interestingly, the proportion of diabetic patients using metformin but not insulin was significantly higher in the non-severe COVID-19 cohort (p<0.05). **Discussion and conclusion**: Our findings were in line with previously reported risk factors for severe COVID-19. NLP in combination with other data mining approaches appears to be a suitable tool for the automated real-time detection of risk factors, which can be a time saving support for risk assessment and

- 50 triage, especially in patients with long medical histories and multiple
- 51 comorbidities.

# 1 BACKGROUND

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Coronavirus disease 19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in Wuhan, China, in December 2019,(1) and spread globally with rising numbers of cases and deaths.(2) Several risk factors have been identified for severe COVID-19 disease and need to be taken into consideration when assessing patients in the early stages since they can affect the clinical outcome and are therefore important for patient triage and management decisions. Some of the reported risk factors, such as age,(3, 4) sex,(5, 6) or obesity,(7-10) are included in tabulated form in the electronic health records (EHRs). However, information on other relevant comorbidities such as diabetes,(11-13) cardiac(14-16) and pulmonary diseases, (17, 18) cancer, (19) or dementia (20) is usually included as free-text in the medical history of the EHR and can be time consuming to retrieve. This holds in particular in patients with a long medical history and conditions that might not be included separately in the list of diagnoses (e.g. pre-diabetes). Encoding into ICD (International Classification of Diseases) identifiers – which would be highly suitable for machine processing - is often performed only after discharge or death of the patient and is thus not readily available for the risk evaluation on admission, requires human intervention, and might also only include the main diagnoses relevant to billing purposes. Here we propose a real-time support for patient triage by automatically identifying relevant risk factors for infection with SARS-CoV-2 and for the development of severe COVID-19 (i.e. need for critical care, mechanical

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

93

94

95

96

97

98

ventilation support, or death of any cause). A combination of data mining and natural language processing (NLP) was used to analyse different parts of the EHRs. Structured (tabulated) administrative, demographic and laboratory data as well as unstructured (free-text) medical history information were processed to identify specific risk factors (age, sex, high BMI, diabetes, cardiovascular disease, pulmonary disorders, dementia, cancer, and decreased kidney and liver function) for SARS-CoV-2 infection or severe courses of COVID-19.(15-17, 21, 22) Furthermore, for diabetic patients, the treatment regimen (untreated, insulin, oral anti-diabetics (OAD) or combination of insulin and OAD) on admission was taken into consideration to classify disease severity. After development and internal validation, these methods were used in a retrospective analysis of patients seen at the Insel Hospital Group (IHG) in Switzerland, a tertiary hospital network and the biggest health care provider in Switzerland with six locations and about 860'000 patients treated per year. Patients who received testing for SARS-CoV-2 at any point during the 'first' and 'second' waves of the pandemic in 2020 were included.

# 92 2 METHODS

#### 2.1 Study population

The study was carried out at the IHG. The protocol was approved by the Cantonal Ethics Committee of Bern (Project-ID 2020-00973). We considered all individuals tested for SARS-CoV-2 at the IHG between February 1<sup>st</sup> through November 16<sup>th</sup> 2020– covering the 'first wave' and part of the 'second wave' of COVID-19 in the country, and who did not reject the IHG general research

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

consent. For patients with no registered general research consent status, a waiver of consent was granted by the ethics committee. Patients who objected to the general research consent of the IHG were excluded from the study. Participation in other trials (including COVID-19 related treatment studies) was not an exclusion criterion and was not recorded separately. A reversetranscriptase polymerase chain reaction (RT-PCR) assay on nasopharyngeal swabs was in use throughout the entire observational period as diagnostic test for SARS-CoV-2 detection. Detailed information on the selection of the study population is provided in Figure 1. All patients had been discharged or died by the time of the analysis. Patients were classified according to their test result and disease severity, with the worst outcome at any point determining the class: Negative: Patients who always tested negative for SARS-CoV-2 Positive: Patients who tested positive for SARS-CoV-2 at any point o *Non-severe*: Patients who tested positive for SARS-CoV-2, but were neither admitted to the intensive care unit (ICU) nor died of any cause during their hospital stay. Severe: Composite outcome for patients who tested positive for SARS-CoV-2 and required ICU admission at any stage during the disease or died of any cause during their hospital stay. Given that the study was retrospective and observational, sample sizes were dictated by the dynamics of the pandemic in the greater Bern region. Consequently, no formal power calculations were performed a priori.

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

The NLP validation dataset consisted of 138 patients, who were tested positive for SARS-CoV-2 during the first wave in Switzerland (February - August 2020) and whose medical history were available. The EHR was screened manually by two of the authors for the following comorbidities of interest: arterial hypertension, chronic heart failure, atrial fibrillation or flutter, coronary heart disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes (including type I, type II and pre-diabetes), dementia (including mild cognitive impairment), and cancer.(15-17, 21, 22)

#### 2.1.1 Data mining and Natural Language Processing

Age and sex were taken directly from the structured parts of the EHR. Although BMI was also included in the structured parts, some values were not correctly calculated. Therefore, BMI were recalculated using weight and height, which are also documented in the EHR, after removing highly unrealistic values (e.g. weight of 80 kg for a <1 year old child or height of 16.3 cm for an adult), which were probably due to typing errors. Laboratory values indicative for kidney failure (estimated glomerular filtration rate (GFR) according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation) or hepatic dysfunction (alanine aminotransferase (ALAT) and alkaline phosphatase (AP)) were also taken from the structured parts of the EHR. We used the lowest and highest values measured, respectively, in the time frame between three days before and one day after the Sars-CoV-2 test as described in a previous study.(23) Kidney function was categorized into five stages: normal (GFR ≥ 90 mL/min), mild impairment (GFR 60-89 mL/min), moderate impairment (GFR 30-59 mL/min), severe impairment (GFR 15-29 mL/min) and kidney failure (GFR < 15 mL/min).(24) Liver function was considered as

impaired if ALAT > 90 U/L (~3x ULN (upper limit of normal)) and/or

#### NLP COVID-19, Schöning (2021)

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

 $AP > 200 \text{ U/L } (\sim 2x \text{ ULN}).$ The comorbidities of interest were identified in the medical history, which is the unstructured, free-text part of the EHR. In a first step, we merged the information of different time points into a single text file per patient and removed duplicate sentences. We then read the text files into Python as data corpus, where we performed the actual NLP (Figure 2). General data cleaning of these files consisted of converting special characters (e.g. umlauts such as 'a' to 'ae'), setting the whole text to lower case, and removing dates. Then sentences were tokenized, i.e. the text was separated into single (half-) sentences (tokens). Tokens with less than two characters or information related to family history were removed. As the medical history consisted mainly of catch phrases and half-sentences, we decided against a removal of stop words. For each disease, a specific list of key terms was generated, which consisted of common terms (one or more words) and abbreviations used to describe the diseases in German EHR systems. As there are many different terms for the diverse types of cancer, another approach was chosen for this element. We first scanned all EHRs for words containing cancer-specific terms such as 'cancer', 'carcinoma', or 'neoplasia', and created a key terms list. This list was then appended with other common terms and abbreviations for specific types of cancer, for instance 'ALL' for acute lymphoblastic leukaemia. For correction of spelling errors and lemmatization, the key terms list was transformed into a dictionary, where each word only appears once. Words within the medical history were replaced with the corresponding word of the dictionary when the similarity threshold of the Levenshtein distance (minimum number of characters required to transform

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

one word to another) was equal or bigger than 90%. Then, for each token within the medical history, we checked for the presence of the defined key terms. If the key term consisted of more than one word (e.g. 'arterial hypertension'), the algorithm was set to allow up to three words between the single words of the key term. This further reduced the need for removing stop words. If the key term was present, we determined the context of the key term (affirmation or negation) using a German implementation of NegEx.(25) The output of the negation detection was screened, and the negation trigger list appended accordingly where necessary (e.g. 'non-insulin'). In case of an equal or bigger number of affirmed than negated statements, the patient was tagged as 'positive' for the disease. The disease status of each patient as determined by NLP was compared to the manually tagged label. For cases where the automatically detected disease status varied from the manual one, the medical history was screened again, and, if possible, the key term list was corrected accordingly. The NLP detection was considered suitable if the error rate per disease was  $\leq 2\%$ . As the structured medication on admission table was not always filled in, we decided to use a combined approach to identify anti-diabetic treatment: we selected individuals which were identified as diabetes patients by NLP and searched the EHR for key terms of treatment with insulin or OADs. We then combined these NLP results with the medication at admission table. If either the NLP or the medication at admission table showed use of insulin and/or OAD, we tagged the patient as receiving that treatment. If the patient received neither, we categorized the patient as 'untreated'. For the subgroup analysis of the OAD only cohort, we were only able to use the recorded medication on

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

admission to identify metformin, the only biguanide marketed in Switzerland, as medical histories and diagnosis lists often do not mention the specific OAD used. Age, sex, BMI, disease status, anti-diabetic treatment and kidney and liver function of all patients with available information were then analysed and stratified according to the cohorts described above. 2.1.2 Software and statistical tests NLP was performed in Python (version 3.8.5). The text file corpus was generated using the Natural Language Toolkit (nltk) package (version 3.5).(26) Steps requiring regular expressions (e.g. text cleaning, sentence tokenization, word replacement) were performed using the re package (version 2.2.1). For spelling correction and lemmatization, we used the FuzzyWuzzy package (version 0.18.0) and specific, manually generated keyword lists. Detection of negation was performed using NegEx(27) in combination with its German implementation.(25) Data wrangling, analysis and visualization was performed in GNU R (version 4.0.2, R Foundation for Statistical Computing, http://www.R-project.org, Vienna, Austria). Standard statistics, e.g. Shapiro-Wilk test, Chi square, Fisher's exact test, Wilcoxon rank sum test, were conducted using the stats package (version 4.0.2). Comparisons were performed between a) patients tested negative and positive for SARS-CoV-2 and b) patients with a non-severe and severe clinical manifestation of COVID-19. Statistical significance levels were determined using Wilcoxon rank sum test for non-normally distributed parameters, as

confirmed by Shapiro-Wilk test, and the Chi square test or the Fisher's exact test (sample size ≤ 5) for categorical parameters. A p value of <0.05 was considered statistically significant.

# 3 RESULTS

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

A total of 6'250 patients tested for SARS-CoV-2 at the IHG during the study period were included and categorized as either SARS-CoV-2 negative (n=5'664) or positive (n=586), and – among the latter- as having a non-severe (n=461) or severe (n=125) clinical outcome. The comorbidities of interest, i.e. arterial hypertension, chronic heart failure, atrial fibrillation or flutter, coronary heart disease, asthma, COPD, diabetes, dementia and cancer, could be automatically detected in the German EHR of the IHG using NLP with an error rate of ≤ 2% compared to the manually tagged EHR. The results of the validation and the key terms used for each disease are shown in the supplementary material (Table S1 and Table S2). Stratification of patients to the outcome showed that the proportions of patients with old age, male sex, higher BMI, arterial hypertension, or diabetes were significantly higher in the positive SARS-CoV-2 and in the severe COVID-19 cohorts (Table 1). Patients with atrial fibrillation or flutter were more likely to be tested negative for SARS-CoV-2, but despite a tendency for more severe clinical manifestations of COVID-19, these results were not significant. The same proportion of patients with coronary heart disease was tested negative and positive for SARS-CoV-2, but with a higher proportion of patients with a severe course.

244

245

# Table 1: Distribution of risk factors as determined by automated analysis of the Electronic Health Records (EHRs)

	Test for SARS-CoV-2		COVID-19 clinical manifestation			
	negative	positive		non-	severe	
	(N = 5'664)	(N = 586)	p-value	severe (N = 461)	(N = 125)	p-value
Age (years)						
Median (IQR)	63 (39, 77)	65 (48, 77)	0.013 <sup>\$</sup>	62 (44, 75)	69 (59, 81)	<0.002\$
Sex						
Female (%)	2'650 (46.8%)	246 (42.0%)	0.029*	211 (45.8%)	35 (28.0%)	<0.002*
ВМІ						
Median (IQR)	24.6 (21.1, 28.7)	26.5 (23.5, 29.7)	<0.002\$	25.9 (23.2, 29.4)	27.9 (24.8, 30.9)	0.003\$
Diseases						
аНТ (%)	2,270 (40.1%)	270 (46.1%)	0.006*	192 (41.7%)	78 (62.4%)	<0.002*
Chronic heart failure (%)	1,591 (28.1%)	140 (23.9%)	0.035*	97 (21.0%)	43 (34.4%)	0.003*
Atrial fibrillation or flutter (%)	1,025 (18.1%)	84 (14.3%)	0.027*	59 (12.8%)	25 (20.0%)	0.058*
Coronary heart disease (%)	1,052 (18.6%)	92 (15.7%)	0.098*	56 (12.2%)	36 (28.8%)	<0.002*
Asthma (%)	350 (6.2%)	52 (8.9%)	0.015*	45 (9.8%)	7 (5.6%)	0.203*
COPD (%)	612 (10.8%)	45 (7.7%)	0.023*	28 (6.1%)	17 (13.6%)	0.009*
Diabetes (%)	1,129 (19.9%)	155 (26.5%)	<0.002*	111 (24.1%)	44 (35.2%)	0.017*
Dementia (%)	516 (9.1%)	55 (9.4%)	0.885*	40 (8.7%)	15 (12.0%)	0.339*
Cancer (%)	1,407 (24.8%)	96 (16.4%)	<0.002*	73 (15.8%)	23 (18.4%)	0.582*
Kidney function						
Normal, GFR >90 mL/min (%)	2,131 (36.16%)	196 (32.13%)	0.054	163 (36.22%)	33 (20.62%)	< 0.002
Mild impairment, GFR 60-89 mL/min (%)	1,871 (31.74%)	239 (39.18%)	<0.002*	187 (41.56%)	52 (32.50%)	0.055
Moderate impairment, GFR 30-59 mL/min (%)	1,299 (22.04%)	116 (19.02%)	0.095	77 (17.11%)	39 (24.38%)	0.058

	Test for SA	RS-CoV-2		COVID-19 clinical manifestation		
	negative (N = 5'664)	positive (N = 586)	p-value	non- severe (N = 461)	severe (N = 125)	p-value
Severe impairment, GFR 15-29 mL/min (%)	385 (6.53%)	37 (6.07%)	0.720	13 (2.89%)	24 (15.00%)	<0.002*
Kidney failure, GFR <15 mL/min (%)	208 (3.53%)	22 (3.61%)	1	10 (2.22%)	12 (7.50%)	0.005*
Liver function  Elevated liver  enzymes (%)	837 (16.89%)	74 (13.99%)	0.101	30 (9.62%)	26 (26.26%)	<0.002*
Diabetes management						
Untreated (%)	336 (29.8%)	38 (24.5%)	0.210*	27 (24.3%)	11 (25.0%)	1*
Insulin and OADs (%)	258 (22.9%)	43 (27.7%)	0.213*	30 (27.0%)	13 (29.6%)	0.907*
Insulin only (%)	231 (20.5%)	23 (14.8%)	0.124*	10 (9.0%)	13 (29.6%)	0.003*
OAD only (%)	304 (26.9%)	51 (32.9%)	0.143*	44 (39.6%)	7 (15.9%)	0.008*
Incl. metformin (%)	-	-	-	21 (18.9%)	2 (4.6%)	0.024**
Excl. metformin (%)	-	-	-	23 (20.7%)	5 (11.46%)	0.247**

Bold numbers indicate significant differences (p <0.05) between compared groups. aHT: arterial hypertension, BMI: body mass index, COPD: chronic obstructive pulmonary disease, GFR: glomerular filtration rate, IQR: interquartile range, OAD: oral anti-diabetics, \$ Wilcoxon rank sum test, \* Chi Square test \*\*Fisher test

Patients suffering from chronic heart failure or COPD were less likely to be tested positive for SARS-CoV-2, but more likely to develop a severe COVID-19 course. In contract, significantly more asthmatic patients were tested positive for SARS-CoV-2 than negative. However, with regards to clinical manifestation, no difference could be observed between the two groups. Cancer patients were less likely to be tested positive for SARS-CoV-2, but no significant difference in severity was observed.

Diabetes treatment was not associated with the risk for tested positive for SARS-CoV-2, but with its clinical consequences. Treatment with OAD only was significantly associated with less cases of a severe outcome, whereas treatment with insulin only showed the opposite effect. A subgroup analysis of the OAD only group showed that this effect might be linked to metformin. No differences were seen for untreated and insulin/OAD co-medicated patients.

Normal kidney function around the time of SARS-CoV-2 testing was associated with benign courses, whereas a severely impaired kidney function of kidney failure was more often seen in severe cases. Additionally, elevated liver enzymes were also seen more often in cases with severe COVID-19.

# 4 DISCUSSION

During the ongoing pandemic, the swift identification of patients at risk for infection and severe courses of COVID-19 is highly important. Manual identification of risk factors is a time-consuming task, especially for patients with co-morbidities, as the respective medical histories might be very long. Using NLP on EHRs poses several challenges, as written clinical text contains abbreviations, acronyms, spelling errors, and nested negations.(28) Furthermore, most available software solutions focus on English language text. We were able to develop a suitable NLP algorithm to automatically detect relevant risk factors for COVID-19 in the medical history of patients at time of admission. The selected key terms allowed for a detection in German EHRs with an error rate of  $\leq 2\%$  on the validation dataset and thus can be used for automated real-time detection to support risk assessment and triage at point-of-care.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

Old age, male sex, higher BMI, arterial hypertension, and diabetes were identified as risk factors for a positive COVID-19 test result as well as for a more severe clinical outcome. This is in line with observations of other studies and reviews.(29) Old age is generally accepted as a risk factor for severe clinical manifestations, probably due to coexisting age-dependent risk factors (e.g. diabetes, arterial hypertension, coronary heart disease, malnutrition) and remodelling of the immune system (immunosenecence).(3, 4, 30) Sex-specific differences in immune response during COVID-19 might be responsible for the higher vulnerability of males, (5, 31) but also life style (e.g. personal hygiene and smoking)(32) might contribute to this observation. Obesity is not only associated with other comorbidities such as diabetes and arterial hypertension, but also several physiological changes, e.g. chronic inflammation, endocrinal dysfunction, impaired pulmonary perfusion, and immune dysregulation, which may contribute to severe clinical manifestations. (7-10) Furthermore, several comorbidities can often also coexist and a number of two or more comorbidities were a significant factor for a more severe COVID-19 clinical outcome in previous studies.(33) Diabetes was seen in approximately one third of patients with a severe disease course. This proportion was within the range of other studies.(34, 35) Monotherapy of diabetes before admission in COVID-19 patients with insulin was associated with a higher percentage of severe outcomes (29.6% vs. 9.0%). By contrast, OAD treatment that included metformin was associated with a higher percentage of non-severe disease progression (18.9% vs. 4.6%). This decrease in severity was significant for the metformin group (p < 0.02). OAD treatment that did not include metformin was not significantly associated with

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

disease severity. This is in line with recent clinical reports that metformin treatment of diabetic COVID-19 patients resulted in a reduced mortality rate.(36-38) Metformin acts by activating the AMP-activated protein kinase AMPK,(39) which then phosphorylates angiotensin-converting enzyme 2 (ACE2) causing increase in ACE2 expression (40) Even though ACE2 serves as molecular target for SARS-CoV-2, it also exhibits protective effects.(41-45) Furthermore, AMPK also inhibits the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway that is essential for viral translation. (46) Finally, metformin, inhibits inflammatory pathways and elevated inflammatory immune responses (cytokine storms).(47) Possible reasons for the observation that COPD was associated with lower proportion of a positive test for COVID-19, which is also seen in other published data, (48) include a potential effect of smoking, the most predominant risk factor for the development of COPD. Smokers have been reported to be less susceptible to COVID-19.(49, 50) Furthermore, given the common symptoms of COPD such as cough, increased phlegm, shortness of breath, and decreased oxygen levels, it is also possible that due to the similarity in clinical presentation with a SARS-CoV-2 infection might lead to a higher test rate in COPD patients and thus more negative SARS-CoV-2 test results, while respiratory diseases including COPD might be under-diagnosed in some positively tested cases. (33) A possible protective role of regular treatment with inhaled corticosteroids in patients with COPD or asthma was not confirmed by Schultze et al.(51) Despite the often similar symptoms, and the presence of chronic airway inflammation in both COPD and asthma, the generally better outcomes in cases with asthma might be due to the usually younger age of

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

these patients or to the non-reversible structural changes of the airways in case of COPD. Our study has several limitations. As the IHG is a major hospital centre in the region, patients admitted to the hospital for other reasons were also tested for SARS-CoV-2 if they displayed any symptoms indicative for COVID-19. The patients in the SARS-CoV-2 negative cohort probably have more health-related problems than the general population. This effect is further corroborated as we only analysed patients with available EHRs, and, due to the retrospective nature of the study, had no information on patients tested at the ambulant COVID-19 test centre without being admitted to the IHG as in- or out-patients. This was partially mitigated by including records from the three months preceding diagnosis. Therefore the higher incidence of specific comorbidities in the SARS-CoV-2 negative cohort might represent a selection bias. Additionally, we did not perform a case-controlled study or adjusted for cofounding factors such as smoking or age. Furthermore, with the exception of diabetes and renal function, we did no differentiate between the different stages and severities of the diseases. This issue can be addressed by refining the key terms list in a subsequent study. The validated error rate for the NLP detection of the different disease is around 2%. Due to this low error rate, the pronounced contrast between significant features, and the large amount of EHRs analysed, it is not expected to affect statistical conclusions. The main focus of the analysis were patients tested positive for SARS-CoV-2, and approximately 25% of these patients were used for the validation of NLP and thus manually screened for the diseases of interest.

# 5 CONCLUSION

357

358

359

360

361

362

363

364

365

366

367

368

In conclusion, we were able to develop a suitable NLP algorithm to automatically detect risk factors for COVID-19 in German EHRs at time of admission with an error rate of ≤ 2%. Our technique should be relative easily transferable to other languages by amending the key terms list and the negation detection accordingly. Use of NLP and data mining can provide a timesaving support for risk assessment and triage at point-of-care, especially in patients with long medical histories and multiple comorbidities. In the future, the same technique could also be used for vaccine prioritization for the automated and time efficient identification of persons at risk.

# 6 DECLARATIONS

#### 6.1 Authors' contributions

- 369 FH and VS conceptualized this study. VS and FH performed the data analysis.
- 370 FH and EL contributed to data extraction. All authors critically revised and
- 371 approved the final manuscript.

#### 372 **6.2 Acknowledgements**

- We thank Noel Frey, Myoori Wijayasingham, and the Insel Data Science Center
- for database and infrastructure support.

#### 375 **6.3 Competing interest**

376 None.

6.4 Funding

378 None.

377

379

385

#### 6.5 Ethics approval and consent to participate

- 380 The study was approved by the Cantonal Ethics Committee of Bern (Project-ID
- 381 2020-00973). Participants either agreed to a general research consent or, for
- 382 participants with no registered general research consent status (neither
- 383 agreement nor rejection), a waiver of consent was granted by the ethics
- 384 committee.

#### 6.6 Availability of data and materials

- The datasets used and/or analyses during the current study are available from
- 387 the corresponding author on reasonable request.

# 388 7 REFERENCES

- 1 Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human
- 390 respiratory disease in China. Nature. 2020 2020/03/01;**579**(7798):265-9.
- 391 2 Johns Hopkins University. COVID-19 Dashboard by the Center for Systems
- 392 Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020
- [cited 2020 17.11.2020]; Available from: <a href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</a>
- 394 3 Bencivenga L, Rengo G, Varricchi G. Elderly at time of COronaVIrus disease
- 395 2019 (COVID-19): possible role of immunosenescence and malnutrition.
- 396 GeroScience. 2020 2020/08/01;42(4):1089-92.
- 397 4 Cunha LL, Perazzio SF, Azzi J, Cravedi P, Riella LV. Remodeling of the
- 398 Immune Response With Aging: Immunosenescence and Its Potential Impact
- on COVID-19 Immune Response. Frontiers in immunology. 2020;**11**:1748-.
- 400 5 Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global
- 401 COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature
- 402 communications. 2020 2020/12/09;**11**(1):6317.
- 403 6 Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F.
- 404 Biological sex impacts COVID-19 outcomes. PLOS Pathogens.
- 405 2020;**16**(6):e1008570.
- 406 7 Kang Z, Luo S, Gui Y, et al. Obesity is a potential risk factor contributing to
- 407 clinical manifestations of COVID-19. International journal of obesity. 2020
- 408 Dec;**44**(12):2479-85.

- 409 8 Kwok S, Adam S, Ho JH, et al. Obesity: A critical risk factor in the COVID-19
- 410 pandemic. Clinical obesity. 2020 Dec; **10**(6):e12403.
- 411 9 Foldi M, Farkas N, Kiss S, et al. Obesity is a risk factor for developing critical
- 412 condition in COVID-19 patients: A systematic review and meta-analysis.
- 413 Obesity reviews: an official journal of the International Association for the Study
- 414 of Obesity. 2020 Oct;**21**(10):e13095.
- 415 10 Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe
- 416 COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020 Jul
- 417 7;**142**(1):4-6.
- 418 11 Zhu L, She Z-G, Cheng X, et al. Association of Blood Glucose Control and
- 419 Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell
- 420 metabolism. 2020 2020/06/02/;**31**(6):1068-77.e3.
- 421 12 Tadic M, Cuspidi C. The influence of diabetes and hypertension on outcome
- in COVID-19 patients: Do we mix apples and oranges? The Journal of Clinical
- 423 Hypertension. 2020 2020/12/25;**n/a**(n/a).
- 424 13 Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from
- pathophysiology to clinical management. Nature Reviews Endocrinology. 2021
- 426 2021/01/01;**17**(1):11-30.
- 427 14 Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease,
- 428 Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020 Jun
- 429 18;**382**(25):e102.
- 430 15 Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM.
- 431 Association of cardiovascular disease and 10 other pre-existing comorbidities
- with COVID-19 mortality: A systematic review and meta-analysis. PLOS ONE.
- 433 2020;**15**(8):e0238215.
- 434 16 Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of
- patients hospitalized for COVID-19 and cardiac disease in Northern Italy.
- 436 European Heart Journal. 2020;**41**(19):1821-9.
- 437 17 Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects
- in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
- 439 International Journal of Infectious Diseases. 2020 2020/05/01/;94:91-5.
- 440 18 Olloquequi J. COVID-19 Susceptibility in chronic obstructive pulmonary
- 441 disease. European Journal of Clinical Investigation. 2020
- 442 2020/10/01;**50**(10):e13382.
- 443 19 Desai A, Khaki AR, Kuderer NM. Use of Real-World Electronic Health
- 444 Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in
- Patients With Cancer. JAMA Oncology. 2021;7(2):227-9.
- 446 20 Wang Q, Davis PB, Gurney ME, Xu R. COVID-19 and dementia: Analyses
- 447 of risk, disparity, and outcomes from electronic health records in the US.
- 448 Alzheimer's & Dementia. 2021 2021/02/09; **n/a**(n/a).
- 449 21 Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A
- 450 systematic review and meta-analysis to evaluate the impact of various
- 451 comorbidities on serious events. Diabetes & Metabolic Syndrome: Clinical
- 452 Research & Reviews. 2020 2020/09/01/;**14**(5):1017-25.
- 453 22 Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The Impact of Dementia on
- 454 the Clinical Outcome of COVID-19: A Systematic Review and Meta-Analysis.
- 455 Journal of Alzheimer's Disease. 2020;**78**:1775-82.
- 456 23 Schöning V, Liakoni E, Baumgartner C, et al. Development and validation of
- 457 a prognostic COVID-19 severity assessment (COSA) score and machine

- 458 learning models for patient triage at a tertiary hospital. Journal of Translational
- 459 Medicine. 2021 2021/02/05;**19**(1):56.
- 460 24 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic
- 461 kidney disease: evaluation, classification, and stratification. Am J Kidney Dis
- 462 2002;**39**(2 Suppl 1):S1-266.
- 463 25 Cotik V, Roller R, Xu F, Uszkoreit H, Budde K, Schmidt D. Negation
- 464 Detection in Clinical Reports Written in German; 2016.
- 465 26 Bird S, Klein E, Loper E. Natural Language Processing with Python: O'Reilly
- 466 Media, Inc.; 2009.
- 467 27 Chapman WW, Bridewell W, Hanbury P, Cooper GF, Buchanan BG. A
- 468 Simple Algorithm for Identifying Negated Findings and Diseases in Discharge
- 469 Summaries. Journal of Biomedical Informatics. 2001 2001/10/01/;**34**(5):301-10.
- 470 28 Dalianis H. Clinical Text Mining: Secondary Use of Electronic Patient
- 471 Records: Springer Nature; 2018.
- 472 29 Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity
- and fatality: a structured literature review. Infection. 2020 2020/08/28.
- 474 30 Romero Starke K, Petereit-Haack G, Schubert M, et al. The Age-Related
- 475 Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-
- 476 Analysis, and Meta-Regression. International Journal of Environmental
- 477 Research and Public Health. 2020;**17**(16):5974.
- 478 31 Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune
- 479 responses that underlie COVID-19 disease outcomes. Nature. 2020
- 480 2020/12/01;**588**(7837):315-20.
- 481 32 Anca PS, Toth PP, Kempler P, Rizzo M. Gender differences in the battle
- 482 against COVID-19: Impact of genetics, comorbidities, inflammation and lifestyle
- 483 on differences in outcomes. International Journal of Clinical Practice. 2021
- 484 2021/02/01;**75**(2):e13666.
- 485 33 Guan W-i, Liang W-h, Zhao Y, et al. Comorbidity and its impact on 1590
- 486 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory
- 487 Journal. 2020:2000547.
- 488 34 Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically III
- 489 Patients in the Seattle Region Case Series. N Engl J Med. 2020 May
- 490 21;**382**(21):2012-22.
- 491 35 Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically
- 492 III Patients With COVID-19 in Washington State. Jama. 2020; 323(16):1612-4.
- 493 36 Nafakhi H, Alareedh M, Al-Buthabhak K, Shaghee F, Nafakhi A, Kasim S.
- 494 Predictors of adverse in-hospital outcome and recovery in patients with
- 495 diabetes mellitus and COVID-19 pneumonia in Iraq. Diabetes Metab Syndr.
- 496 2020 Dec 5;**15**(1):33-8.
- 497 37 Lally MA, Tsoukas P, Halladay CW, O'Neill E, Gravenstein S, Rudolph JL.
- 498 Metformin is Associated with Decreased 30-Day Mortality Among Nursing
- 499 Home Residents Infected with SARS-CoV2. J Am Med Dir Assoc. 2021
- 500 Jan;**22**(1):193-8.
- 501 38 Kow CS, Hasan SS. Mortality risk with preadmission metformin use in
- 502 patients with COVID-19 and diabetes: A meta-analysis. J Med Virol. 2021
- 503 Feb;**93**(2):695-7.
- 504 39 Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase:
- 505 ancient energy gauge provides clues to modern understanding of metabolism.
- 506 Cell Metab. 2005 Jan; 1(1):15-25.

- 507 40 Saheb Sharif-Askari N, Saheb Sharif-Askari F, Mdkhana B, et al. Effect of
- 508 common medications on the expression of SARS-CoV-2 entry receptors in liver
- 509 tissue. Arch Toxicol. 2020 Dec; **94**(12):4037-41.
- 41 Behl T, Kaur I, Bungau S, et al. The dual impact of ACE2 in COVID-19 and
- 511 ironical actions in geriatrics and pediatrics with possible therapeutic solutions.
- 512 Life Sci. 2020;**257**:118075-.
- 513 42 Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of
- 514 ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020; **157**:104833-.
- 515 43 Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a
- 516 peptidase in the renin-angiotensin system, a SARS receptor, and a partner for
- amino acid transporters. Pharmacol Ther. 2010;128(1):119-28.
- 518 44 Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from
- severe acute lung failure. Nature. 2005 2005/07/01;**436**(7047):112-6.
- 520 45 Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2
- 521 (ACE2) in COVID-19. Critical Care. 2020 2020/07/13;**24**(1):422.
- 522 46 Karam BS, Morris RS, Bramante CT, et al. mTOR inhibition in COVID-19: A
- 523 commentary and review of efficacy in RNA viruses. J Med Virol. 2021
- 524 Apr; **93**(4): 1843-6.
- 525 47 Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and
- 526 Antiviral Activity of Metformin and Its Potential Implications in Treating
- 527 Coronavirus Disease 2019 and Lung Injury. Front Immunol. 2020;11:2056.
- 528 48 Deslée G, Zysman M, Burgel PR, et al. Chronic obstructive pulmonary
- 529 disease and the COVID-19 pandemic: Reciprocal challenges. Respir Med Res.
- 530 2020;**78**:100764-.
- 49 Tajlil A, Ghaffari S, Pourafkari L, Mashayekhi S, Roshanravan N. Nicotine
- and smoking in the COVID-19 era. J Cardiovasc Thorac Res. 2020;**12**(2):136-
- 533 9.
- 534 50 Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of
- 535 current smoking among hospitalized COVID-19 patients in China: could
- 536 nicotine be a therapeutic option? Internal and emergency medicine. 2020
- 537 Aug; **15**(5):845-52.
- 538 51 Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death
- 539 among patients with chronic obstructive pulmonary disease or asthma
- 540 prescribed inhaled corticosteroids: an observational cohort study using the
- 541 OpenSAFELY platform. The Lancet Respiratory Medicine. 2020;8(11):1106-20.

# 542 8 FIGURES




Figure 1: Flowchart of the selection of the patient population included in the study



Figure 2: Data preparation steps for the detection of diseases in a free-text medical history

543

544

545

547

548

# 9 SUPPLEMENTARY MATERIAL

- **Table S1:** Overview on error rate of Natural Language Processing (NLP)
- 552 detection of disease status on the validation dataset and the final key terms
- 553 used for NLP.

Disease	Error rate on validation dataset (138 cases)	Key terms
Diabetes	0.7% (1/138)	diabetes, diabetisch, praediabetisch, praediabetes, mellitus, zuckerkrankheit, gestationsdiabetes
аНТ	0.7% (1/138)	aht, arterielle hypertonie, hypertensive kardiopathie, hypertensive herzkrankheit, arterielle hypertonus, arterielle hypertension, hypertensive entgleisung, bluthochdruck, hypertensive notfall
Asthma	1.4% (2/138)	asthma, asthma bronchiale, bronchialasthma, belastungsasthma, belastungsasthma bronchiale
COPD	0.7% (1/138)	chronisch obstruktive pneumopathie, chronisch obstruktive atemwegserkrankung, chronisch obstruktive lungenerkrankung, copd, chronisch obstruktive bronchitis, chronisch bronchitis emphysem, chronisch obstruktive lungenkrankheit, obstruktive ventilationsstoerung, chronisch bronchitis lungenemphysem
Chronic heart failure	0.7% (1/138)	herzinsuffizienz, kardiomyopathie, kardiopathie, nyha, lfef, linksherzinsuffizienz, rechtsherzinsuffizienz, hypertensive herzkrankheit, hfref, hfmref, hfpef
Atrial fibrillation	0.7% (1/138)	vorhofflimmern, vhf, vorhofflattern, afib, vfli, vofli, vhfli, vfla, vhfla, vofla, ehra
Coronary heart disease	1.4% (2/138)	koronare herzerkrankung, khk, koronare herzkrankheit,stemi, nstemi, akute koronarsyndrom, acs, myokardiale minderperfusion,chronische koronarsyndrom, koronarstenose, ccs ii, ccs 2, ccs iii, ccs 3, ccs iv, ccs 4, instabile angina pectoris, ischaemische herzkrankheit, ischaemische herzerkrankung, ihk, koronaratheromatose, koronare gefaesserkrankung, koronare kardiopathie, myokardinfarkt
Dementia	1.4% (2/138)	demenz, dementielle, demenzielle, mild cognitive impairment, kognitive stoerung, mci, alzheimer, dement,kognitive beeintraechtigung, lewy

Disease	Error rate on validation dataset (138 cases)	Key terms
Cancer	2.1% (3/138)	Key terms according to Supplementary Material Table S2
Insulin	-	insulin, insulinpflichtig, insulinabhaengig, basisinsulintherapie, insulintherapie, insulinpumpe, insulinperfusor, insulinbasistherapie, levemir, novorapid, lantus, tresiba, toujeo, iddm]
OAD	-	oad, metformin, orale anti diabetikum, orale antidiabetikum, biguanid, glitazone, sulfonylharnstoffe, glinide, inkretine, alpha glucosidasehemmer, dpp 4 inhibitor, sglt 2 inhibitor, orale antidiabetika, sitagliptin, janumet, kombiglyze

Table S2: Key terms for the detection of cancer

Key terms
adenokarzinom
adenokarzinomatoes
adenokarzinominfiltrate
adenokarzinomzellen
adenomkarzinom
adenomkarzinominfiltrate
aderhautmelanom
adnexkarzinom
aktinische keratose
akustikusneurinom
all
alveolarzellkarzinom
aml
analkarzinom
analkrebs
angiosarkom
antrumkarzinom
astrozytom
augentumor
basaliom
basalkarzinom

554

basalzellkarzinom bauchspeicheldruesenkrebs bauchspeichelkrebs blasenkarzinom blasenkarzinom, harnblasenkarzinom bronchialkarzinom bronchuskarzinom bronchuskarzinom brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom diodenalkarzinom eierstockkrebs endometriumkarzinom endometriumkarzinomrezidiv ependymome ewing sarkom ewingsarkom	Key terms
bauchspeichelkrebs blasenkarzinom blasenkarzinom, harnblasenkarzinom bronchialkarzinom bronchuskarzinom brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom diodenalkarzinom diodenalkarzinom diodenalkarzinom eierstockkrebs endometriumkarzinom endometriumkarzinomrezidiv ependymome ewing sarkom	basalzellkarzinom
blasenkarzinom, harnblasenkarzinom bronchialkarzinom bronchuskarzinom bronchuskarzinom brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom colonkarzinom darmkrebs denokarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom duodenalkarzinom duodenalkarzinom eierstockkrebs endometriumkarzinom endometriumkarzinomrezidiv enendymome ewing sarkom	bauchspeicheldruesenkrebs
blasenkarzinom, harnblasenkarzinom bronchialkarzinom bronchuskarzinom bronchuskarzinom brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom colonkarzinom darmkrebs denokarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom diondarmkarzinom diondarmkarzinom diondenalkarzinom eierstockkrebs endometriumkarzinom endometriumkarzinom endometriumkarzinomrezidiv ependymome ewing sarkom	bauchspeichelkrebs
bronchialkarzinom bronchuskarzinom brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom colonkarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom diondarmkrebs doppelkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom diondarmkarzinom diondarmkarzinom diondenalkarzinom eierstockkrebs endometriumkarzinom endometriumkarzinom endometriumkarzinomrezidiv ependymome ewing sarkom	blasenkarzinom
bronchuskarzinom brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom diondarmkarzinom dionderniodesadenokarzinom eierstockkrebs endometriumkarzinom endometriumkarzinomrezidiv ependymome ewing sarkom	blasenkarzinom, harnblasenkarzinom
brustkrebs burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dichopelkarzinom dinndarmkarzinom diondenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	bronchialkarzinom
burkitt lymphom cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dichdarmkarzinom dindarmkarzinom dindarmkarzinom dindarmkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	bronchuskarzinom
cervixkarzinom cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dindarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	brustkrebs
cholangiokarzinom chondrosarkom chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom	burkitt lymphom
chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dickdarmkarzinom dichdarmkarzinom	cervixkarzinom
chondrosarkom chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumskarzinom endometriumskarzinom endometriumskarzinom endometriumskarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	cholangiokarzinom
chondrosarkomanteilen ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dinndarmkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinom endometriumkarzinom endometriumkarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	chondrosarkom
ciliarkoerpermelanom cll cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dichdarmkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinom endometriumskarzinom endometriumskarzinom endometriumskarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	chondrosarkom
colonkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom dünndarmkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	chondrosarkomanteilen
cml coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom dünndarmkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	ciliarkoerpermelanom
coecumkarzinom colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom dünndarmkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	cll
colonkarzinom corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom dundenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	cml
corpuskarzinom darmkrebs denokarzinom dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom dünndarmkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	coecumkarzinom
darmkrebs  denokarzinom  dermatofibrosarkoms  dickdarmkarzinom  dickdarmkarzinom  dickdarmkrebs  doppelkarzinom  dünndarmkarzinom  duodenalkarzinom  eierstockkrebs  endometrioidesadenokarzinom  endometriumkarzinom  endometriumkarzinomrezidiv  endometriumskarzinomrezidiv  ependymome  ewing sarkom	colonkarzinom
denokarzinom  dermatofibrosarkoms  dickdarmkarzinom  dickdarmkrebs  doppelkarzinom  dünndarmkarzinom  duodenalkarzinom  eierstockkrebs  endometrioidesadenokarzinom  endometriumkarzinomm  endometriumkarzinomm  endometriumkarzinomm  endometriumkarzinomm  endometriumkarzinommezidiv  endometriumskarzinomrezidiv  ependymome  ewing sarkom	corpuskarzinom
dermatofibrosarkoms dickdarmkarzinom dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	darmkrebs
dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom dünndarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	denokarzinom
dickdarmkarzinom dickdarmkrebs doppelkarzinom dünndarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	dermatofibrosarkoms
dickdarmkrebs doppelkarzinom dünndarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	dickdarmkarzinom
doppelkarzinom dünndarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	dickdarmkarzinom
dünndarmkarzinom duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	dickdarmkrebs
duodenalkarzinom eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	doppelkarzinom
eierstockkrebs endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	dünndarmkarzinom
endometrioidesadenokarzinom endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	duodenalkarzinom
endometriumkarzinom endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	eierstockkrebs
endometriumkarzinomrezidiv endometriumskarzinomrezidiv ependymome ewing sarkom	endometrioidesadenokarzinom
endometriumskarzinomrezidiv ependymome ewing sarkom	endometriumkarzinom
ependymome ewing sarkom	endometriumkarzinomrezidiv
ewing sarkom	endometriumskarzinomrezidiv
-	ependymome
ewingsarkom	ewing sarkom
	ewingsarkom

Key terms
fibrosarkom
gallenblasenkarzinom
gallengangkarzinom
gastrointestinale stromakarzinom
gebaermutterhalskrebs
gebaermutterhalskrebs
gebaermutterkoerperkarzinom
gebaermutterkrebs
gehirntumor
genkarzinom
gist
glioblastom
gliome
haarzelleukaemie
haemangiosarkom
harnblasenkarzinom
harnroehrenkarzinom
hautkarzinomen
hautkrebs
hautkrebsnekrosen
hautkrebssetomelanomm
hemangiosarkom
hirntumor
hodenkarzinom
hodgkin
hypopharynxkarzinom
hypopharynxkarzinoms
hypophysentumor
kardiakarzinom
karzinoid
karzinom
karzinoma
karzinomablegers
karzinomanteile
karzinomatoese
karzinomatosa
karzinomatose

Key terms
karzinomdiagose
karzinome
karzinomgewebe
karzinomherd
karzinominfiltrate
karzinominfiltration
karzinomlaenge
karzinomnachweis
karzinomresektion
karzinomrezidiv
karzinomsuspekte
karzinomtypisch
karzinomvolumens
karzinomzellen
karzinomzellverbaende
karzinosarkom
karzinosarkoms
kehlkopfkarzinom
keimzellneoplasie
knochenkrebs
kolonkarzinom
kolorektalkarzinom
korpuskarzinom
krebs
krebsbehandlung
krebsdiagnose
krebserkrankung
krebserkrankungen
krebskrank
larynxkarzinom
leberkrebs
leberzellkrebs
leiomyosarkom
leukaemie
leukaemiediagnose
leukaemieinfiltrate
leukaemieklonspezifischen

Key terms
leukaemiepersistenz
leukaemierezidiv
leukaemiezellen
leyomyosarkom
lidtumor
liposarkom
liposarkomanteile
lippentumor
lungenadenokarzinom
lungenkarzinom
lungenkrebs
lymphangiokarzinomatose
lymphdruesenkrebs
lymphgranulomatose
lymphomlymphknotenmetastasenprogression
magenkarzinom
magenkrebs
malignes myelom
mammakarzinom
mastdarmkarzinom
medulloblastome
melanom
melanoma
melanomentfernung
melanomexzision
melanomnachweis
melanomzellen
meningeome
mikrokarzinom
mischgliom
morbus kahlermundhoehlenkarzinom
multiple myelom
mycosis fungoides
myxofibrosarkom
nasennebenhoehlentumor
nasentumor
nasopharynxkarzinom

Key terms
nebennierenkarzinom
nebennierenneoplasie
nebenschilddruesenkarzinom
neoplasie
neoplasieassoziert
neoplasiebedingt
neoplasiein
neoplasien
nephroblastom
netzhauttumor
neurinom
neuroblastom
nierenkarzinom
nierenzellkarzinom
nstmammakarzinom
oesophaguskarzinom
oligoastrozytome
oligodendrogliome
organmetastasen
oropharynxkarzinom
osteosarkom
osteosarkom
osteosarkomresektion
ovarialkarzinom
pankeasneoplasie
pankreaskarzinom
pankreaskopfkarzinom
pankreaskopfneoplasie
pankreaskorpuskarzinom
pankreaskorpusneoplasie
pankreasneoplasie
pankreasschwanzkarzinom
papillenkarzinom
paraneoplasie
peniskarzinom
peritonealkarzinom
peritonealkarzinomatose

Key terms
pharynxkarzinom
plasmazellenneoplasie
plasmazellmyelom
plasmazellneoplasie
plasmozytom
plattenepithelkarzinom
plattenepithelkarzinominfiltrate
plattenepithelungenkarzinom
plattenepithelzellkarzinom
plexustumor
primaerkarzinom
primaertumor
promyelozytenleukaemie
prostatakarzinom
prostatakrebs
rachentumor
rektumkarzinom
retinoblastom
rezidivurothelkarzinom
rhabdomyomsarkom
rhabdomyosarkomatoese
samenblasenkarzinom
sarkom
sarkomatoes
sarkomatoide
sarkomgewebe
sarkomresektion
sarkomrezidiv
sarkomrezidivresektion
sarkomzellen
schadelbasismetastase
schaedelmetastase
scheidenkarzinom
schilddruesenkarzinom
schilddruesenneoplasie
siegelringzellkarzinom
sigmakarzinom

Key terms
speicheldruesenkarzinom
speiseroehrenkarzinom
spinaliom
spinalzellkarzinom
stachelzellkarzinomstachelzellkarzinom
stimmlippenkarzinom
synovialsarkom
thymon
thymuskarzinom
tonsillenkarzinom
tritonskarzinoms
tubenkarzinom
unterleibskrebs
urachuskarzinom
urogenitalkarzinom
urothelkarzinomrezidiv
urothelkarzinomzellen
uteruskarzinom
uterussarkom
uurothelkarzinom
vaginalkarzinom
vulvakarzinom
weichteilsarkom
wilmstumor
zervixkarzinom
zervixkarzinomnachsorge
zoekumkarzinom
zungengrundkarzinom
zungenkarzinom
zweitkarzinom
zystadenokarzinom